ABSTRACT
Acute myelogenous leukaemia – diagnosis and treatment
Acute leukaemia is characterised by a very aggressive course and, in the absence of treatment, leads to death of the patient within weeks. Importantly, despite diagnostic advances, particularly in molecular diagnostics, leading to a better understanding and characterisation of individual subtypes of AML, treatment outcomes, especially in elderly patients, are still unsatisfactory.
Piśmiennictwo
1. Hołowiecki J. Białaczki ostre. W: Hellmann A (red.). Interna Szczeklika. Podręcznik Chorób Wewnętrznych. Medycyna Praktyczna, Kraków 2013:1640-54
2. Wierzbowska A. Ostra białaczka szpikowa. Wytyczne postępowania diagnostyczno-terapeutycznego u chorych na nowotwory układu krwiotwórczego. 2020;6(supll. A). Warzocha K (red.). Polskie Towarzystwo Onkologii Klinicznej, Gdańsk 2020:119-44
3. Kata D, Kyrcz-Krzemień S. Ostra białaczka szpikowa – współczesne poglądy na patogenezę, postępowanie diagnostyczne, klasyfikację, stratyfikację prognostyczną i leczenie. Post Nauk Med 2011;24:601-9
4. Saultz J, Garzon R. Acute Myeloid Leukemia: A Concise Review. J Clin Med 2016;5:33
5. Szmajda D, Balcerczak E, Krygier A. Standards of diagnostic and new trends in treatment in patients with acute myeloid leukemia. Acta Haematologica Polonica 2017;48:291-9
6. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424-47
7. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-405
8. Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”? Hematology Am Soc Hematol Educ Program 2014;2014:222-33
9. Macheta A, Chocholska S, Podhorecka M. Metody genetyczne w diagnostyce hematoonkologicznej. Post Hig Med Dosw 2015;69:475-87
10. Mrózek K, Baldus CD, Marcucci G, Bloomfield CD Acute myeloid leukemia prognostic factors: from cytogenetic to chip. Hematology 2005;1:116-22
11. Mrózek K, Marcucci G, Ruppert AS, et al. Molecular heterogeneity and its prognostic significance in acute myeloid leukemia (AML) with normal cytogentics. Ann Hematol 2006; 86:114-7
12. Slovak ML, Kopecky, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/ /Eastern Cooperative Oncology Group study. Blood 2000;96:4075-83
13. Chi J, Costeas P. The Evolution of Genetics Techniques for Leukemia Diagnosis. Adv Tech Biol Med 2015;3:2
14. Prochorec-Sobieszek M. Klasyfikacja i kryteria diagnostyczne nowotworów układu krwiotwórczego. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych 2013. Tom II. W: Krzakowski M, Warzocha K (red.). Polskie Towarzystwo Onkologii Klinicznej, Gdańsk 2013: 670-84
15. Fey MF, Buske C. Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals Oncology 2013;1-6
16. Wierzbowska A, Gołos A. Nowe strategie leczenia poremisyjnego ostrej białaczki szpikowej u dorosłych. Acta Haematol Pol 2011;42:227-33
17. Cheson BD, Bennett JM, Kopecky KJ, et al. International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21(24):4642-9
18. Rowe JM, Kim HT, Cassileth PA, et al. Adult patients with acute myeloid leukemia who achieve. Cancer 2010;116:5012-21
19. Autas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010;28:808-14
20. Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 2012;30(20):2441-8
21. Levis M. Midostaurin approved for FLT3-mutated AML. Blood 2017;129(26):3403-6
22. Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013;31:3360-8
23. Schaich M, Röllig C, Soucek S, et al. Cytarabine dose of 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol 2011;29:2696-702
24. Miyawaki S, Ohtake S, Fujisawa S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood 2011;117:2366-72
25. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903
26. Byrd JC, Ruppert AS, Mrózek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol 2004;22:1087-94
27. Vellenga E, van Putten W, Ossenkoppele GJ, et al. Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK). Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood 2011;118:6037-42
28. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012;9:579-90
29. Pluta A, Robak T, Wrzesien-Kus A, et al. Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly AML patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. Am J Hematol 2017;92:359-66
30. Itzykson R, Gardin C, Pautas C, et al. Acute Leukemia French Association (ALFA). Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica 2011;96:837-44
31. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562-69
32. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 2020;383(7):617-29